Skip to main content
main-content

18.03.2016 | The Science of Prevention (JD Stekler and J Baeten, Section Editors) | Ausgabe 3/2016

Current HIV/AIDS Reports 3/2016

PrEP as Peri-conception HIV Prevention for Women and Men

Zeitschrift:
Current HIV/AIDS Reports > Ausgabe 3/2016
Autoren:
Renee Heffron, Jillian Pintye, Lynn T. Matthews, Shannon Weber, Nelly Mugo
Wichtige Hinweise
This article is part of the Topical Collection on The Science of Prevention

Abstract

Daily oral tenofovir (TDF)-based pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy and recommended for men and women with substantial risk of HIV acquisition. The peri-conception period, the stage prior to pregnancy when condom use is necessarily reduced, has elevated HIV risk that can be mitigated by PrEP use. Data from a randomized trial suggest that peri-conception PrEP use by HIV-seronegative women does not increase the risk of pregnancy loss, birth defects or congenital anomalies, preterm birth, or infant growth faltering. Women considering PrEP use throughout pregnancy must weigh the known increased risk of HIV acquisition with unknown risks of drug effects on infant growth. PrEP has been used safely by HIV-seronegative men with HIV-seropositive female partners who have become pregnant. As an effective user-controlled HIV prevention strategy, PrEP offers autonomy and empowerment for HIV prevention and can be recommended alongside antiretroviral therapy, fertility screening, vaginal self-insemination, intercourse timed to peak fertility, medically assisted reproduction, and other safer conception strategies to provide multiple options. The integration of PrEP into safer conception programs is warranted and will safely reduce HIV transmission to women, men, and children during the peri-conception period.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

Current HIV/AIDS Reports 3/2016 Zur Ausgabe

Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Non-infectious Pulmonary Diseases and HIV

The Global Epidemic (SH Vermund, Section Editor)

Factors Driving the HIV Epidemic in Southern Africa

Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments

  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Allgemeinmedizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.